An2 Therapeutics, Inc. ANTX
Institutional shares held
13.2 Million
0
calls
0
puts
Total value of holdings
$29.9M
$0
calls
$0
puts
Market Cap
$44M
19,402,700
Shares Out.
Institutional ownership
67.98%
# of Institutions
55
We take great care to ensure that the data presented and summarized in this overview for AN2 Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ANTX
View all-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$3.53 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.53 Million0.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.39MShares$3.15 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.81 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.77 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX1.15MShares$2.61 Million0.14% of portfolio
-
Octagon Capital Advisors LP New York, NY1.1MShares$2.5 Million0.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.05MShares$2.38 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA313KShares$709,6360.0% of portfolio
-
Black Rock Inc. New York, NY291KShares$660,7650.0% of portfolio
Latest Institutional Activity in ANTX
Top Purchases
Top Sells
About ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Insider Transactions at ANTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Eric Easom Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,000
+49.47%
|
-
|
|
Mar 15
2024
|
Paul Eckburg Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+36.85%
|
-
|
|
Mar 15
2024
|
Sanjay Chanda Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+49.34%
|
-
|
|
Mar 15
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.45%
|
-
|
|
Mar 15
2024
|
Joshua M Eizen Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+48.04%
|
-
|
|
Mar 15
2024
|
Lucy Day Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+47.31%
|
-
|
|
Jan 18
2024
|
Joseph S Zakrzewski |
SELL
Open market or private sale
|
Indirect |
100,000
-19.77%
|
$1,900,000
$19.11 P/Share
|
|
Jan 16
2024
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
15,907
-4.04%
|
$302,233
$19.65 P/Share
|
|
Jan 16
2024
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
84,093
-4.04%
|
$1,597,767
$19.65 P/Share
|
|
Jan 16
2024
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
100,000
-4.04%
|
$1,900,000
$19.65 P/Share
|
|
Jan 12
2024
|
Robin Shane Readnour Director |
SELL
Open market or private sale
|
Indirect |
1,425
-0.16%
|
$29,925
$21.92 P/Share
|
|
Jan 10
2024
|
Robin Shane Readnour Director |
SELL
Open market or private sale
|
Indirect |
3,669
-0.41%
|
$77,049
$21.93 P/Share
|
|
Jan 09
2024
|
Kevin Michael Krause Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
7,417
-79.49%
|
$148,340
$20.14 P/Share
|
|
Jan 09
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,417
+35.35%
|
$22,251
$3.51 P/Share
|
|
Jan 02
2024
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,777
-56.59%
|
$55,540
$20.09 P/Share
|
|
Jan 02
2024
|
Kevin Michael Krause Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
2,583
-57.44%
|
$51,660
$20.12 P/Share
|
|
Jan 02
2024
|
Kevin Michael Krause Chief Strategy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,583
+36.48%
|
$0
$0.42 P/Share
|
|
Nov 14
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Indirect |
288
-0.07%
|
$4,608
$16.15 P/Share
|
|
Nov 14
2023
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Open market or private sale
|
Direct |
1,522
-0.07%
|
$24,352
$16.15 P/Share
|
|
Nov 14
2023
|
Kabeer Aziz |
SELL
Open market or private sale
|
Indirect |
1,810
-0.07%
|
$28,960
$16.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.04M
Shares
From
9
Insiders
| Open market or private purchase | 1.79M shares |
|---|---|
| Grant, award, or other acquisition | 244K shares |
| Exercise of conversion of derivative security | 10K shares |
Sell / Disposition
566K
Shares
From
6
Insiders
| Open market or private sale | 566K shares |
|---|